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Summary 
Cannabis is a drug mainly consumed for its euphoric effects; users may become happy, 
careless and relaxed. The direct effects of cannabis in sports are performance decreasing, 
but cannabis can be used as a doping agent due to its relaxing properties. For these reasons, 
cannabinoids are prohibited in sports during competition by the World Anti-Doping Agency 
(WADA). 
 
In the context of the fight against doping, urine is screened for the metabolite THC-COOH 
(11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid or carboxy-THC) with a cut-off of 15 
ng/mL as a reporting limit for adverse analytical finding. This criterion does not fully allow a 
differentiation of in- or out-of-competition abuse and might not distinguish between active 
and passive inhalation. 
 
The presence of THC (Delta-9-tetrahydrocannabinol) and THC-OH (11-hydroxy-delta9-
tetrahydrocannabinol) metabolite in urine has been proposed as indicators for recent can-
nabis use. Thus the need to develop and implement a method for detection and quantifica-
tion of THC, THC-OH, and THC-COOH in urine appeared to be necessary in an anti doping 
laboratory. High sensitivity and specificity are required in such analytical method and for 
that purpose a GC-TSQ (Gas chromatography-triple quadrupole) was used. 
 
A method for the detection of the compounds was developed regarding GC-TSQ parame-
ters, sample extraction and conditions of hydrolysis. The method was validated for specifici-
ty, but, due to several problems, it was not possible to fully validate this new method. The 




I would like to thank my supervisor Dr. Norbert Baume and Dr. and PD. Martial Saugy, 
Technical Director of LAD for welcoming me as a master student, and giving me access to all 
necessary laboratory equipment and facilities.  
I would also like to thank Dr. Norbert Baume and Einar Jensen for being my supervisors. I 
would like to thank Dr. Norbert Baume for being very helpful regarding the writing of my 
thesis and for spending a lot of time helping me with different problems in my project.  I 
would like to thank Professor Einar Jensen for establishing the contact between Department 
of Pharmacy and Laboratoire Suisse D`Analyse du dopage, for reading through my thesis and 
giving me good advice. 
I would like to thank everybody working at the LAD for welcoming me and helping me 
with the different problems that occurred during my stay. I want to thank some of you espe-
cially in the connection with my stay: 
- Dr. Emmanuel Strahm and PhD student François Marclay for introducing me to 
the lab and the city, and driving me and my luggage around the first weeks in Lau-
sanne. The help from Dr. Emmanuel Strahm has meant a great deal to me, he has 
introduced me to the GC-TSQ, being involved in my project and always answering 
my questions promptly and with great patience. 
- The PhD students Flavia Badouid and François Marclay for all the discussions re-
garding my project, and for helping me out when everything seemed impossible. 
Flavia have been very helpful regarding practical problems during my stay. 
- Carine Schweizer for good advice and helping me with different instruments on 
the lab. 
Especially, I would like to thank my friend Ida Lange for coming with me to Switzerland, 
for being kind, impulsive and open minded – you have been a perfect exchange-partner! 
 
At last I would like to thank my family and my friends for supporting me. Thanks also to my 
father for reading trough my report, and giving me advice during the writing process. 
Lausanne, May 15th, 2010 







Carboxy-THC: THC-COOH, 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic 
 acid 
CB1:  Cannabinoid 1 
CB2:  Cannabinoid 2 
CIF:  Cannabis influence factor 
CP47,497:  5(1-dimetilheptil – 2 ((1R,3S) – 3 hydroxycyclohexyl)-phenol 
CE:  Collision energy 
EI:  Electron ionization 
EPO:  Erythropoetin 
GC:  Gas chromatography 
GC-MS:  Gas chromatography – Mass spectrometry 
GC-TSQ:  Gas chromatography – Triple quadrupole 
h:  hour 
H. pomata:  Helix Pomata 
ICH: The International Conference on Harmonisation of Technical Re-
quirements for Registration of Pharmaceuticals for Human Use 
IAAF:  International Sport Federation 
IOC:  The International Olympic Committee 
HCl:  Hydrochloric acid 
HP:  Hewlett Packard 
Hrs: Hours 
HU-210: (6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-
 2-yl)- 6a,7,10,10a -tetrahydrobenzo [c]chromen- 1-ol 
INT.STD:  internal standards (THCd3, THC-OHd3, THC-COOHd3) 
JWH-018:  1-pentil-3-(1-naftoil)indol 
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JWH-073:  Naphthalene-1-yl-(1-butylindol-3-yl)methanone 
JWH-200:  2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone) 
JWH-250:  1-[2-(4-Morpholino)ethyl]-3-(1-naphthoyl)indole 
K2HPO4:  Dipotassium hydrogen phosphate 
KH2PO4:  Potassium dihydrogen phosphate 
KOH:  Potassium hydroxide 
LAD:  Laboratoire Suisse d`Analyse du Dopage 
 Swiss Laboratory for Analysis of Doping 
LC:  Liquid chromatography  
LLE:  Liquid liquid extraction 
LLOQ:  Lower limit of quantification 
LOD:  Lowest level of detection 
m/z:  Mass to charge ratio 
MRM:  Multiple reaction monitoring 
MS:  Mass spectrometry  
MSTFA:  N-Methyl-N-(trimethylsilyl)trifluoroacetamide 
NaOH:  Sodium hydroxide 
NL:  Intensity of a signal 
RSD: Relative standard deviation 
Si-CH2CH2CH2NH3
+:  Protonized aminopropyl attached to silica. 
SIM:  Single ion monitoring 
S/N:  Signal to noise ratio 
SPE:  Solid phase extraction 
STD:  standards (THC, THC-OH, THC-COOH) 
THC:  Delta-9-tetrahydrocannabinol 
THCd3:  Delta9-tetrahydrocannabinol-d3 
THC-COOH:  Carboxy-THC, 11-nor9-carboxy-delta-9-tetrahydrocannabinol 
THC-COOHd3:  11-nor9-carboxy-delta9-tetrahydrocannabinol-d3 
THC-COOHd9:   11-nor-9-carboxy-delta9-tetrahydrocannabinol-d9 
THC-OH:  11-hydroxy-delta9-tetrahydrocannabinol 
THC-OHd3:  11-hydroxy-delta9-tetrahydrocannabinol-d3 
THC-TMS:  Delta-9-tetrahydrocannabinol-trimethylsilyl ether 
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THCd3-TMS:  Delta9-tetrahydrocannabinol-d3-trimethylsilyl ether 
THC-COOH-2TMS:  Carboxy-THC, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol-
2trimethylsilyl ether 
THC-COOHd3-2TMS:   11-nor-9-carboxy-delta9-tetrahydrocannabinol-d3-2trimethylsilyl 
ether 
THC-COOHd9-2TMS:   11-nor-9-carboxy-delta9-tetrahydrocannabinol-d9-2trimethylsilyl 
ether 
THC-OH-2TMS:  11-hydroxy-delta9-tetrahydrocannabinol-2trimethylsilyl ether 
THC-OHd3-2TMS:  11-hydroxy-delta9-tetrahydrocannabinol-d3-2trimethylsilyl ether 
TMCS:  Trimethylchlorosilane 
TMS: Trimethylsilyl 
TSQ:  Triple stage quadrupole 
μm:  Microampere 
eV:  Electron volt 
U:  Units 
UiT:  University of Tromsø 
ULOQ:  Upper limit of quantification  
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3 Aim of the thesis 
This work has been done in the Swiss Laboratory for Doping Analyses (LAD) in Switzer-
land. In the context of anti doping analyses, several topics need constantly to be resolved. 
During the 8 months spent in the laboratory, I have focused on the cannabinoids detection 
in urine. 
Presently, the detection of cannabis misuse in sports is based on the urinary detection of 
THC-COOH. A cut-off limit of 15 ng/mL is set by the WADA through the 2009 Code and the 
Prohibition List which is updated every year. This cut-off limit is highly debated as it is diffi-
cult to differentiate between passive and active intake of the drug and also to determine if 
cannabis has been used on purpose to increase the athletics performance or only as a “social 
drug”. 
Numerous authors have already investigated the analysis of cannabinoids in different bio-
logical matrices and the quantification of THC and THC-OH in addition to THC-COOH could be 
helpful to answer the above questions. 
Hence, the first aim of this work was to develop, validate and implement an analytical 
method based on GC-MS/MS (Gas chromatography technology to quantify THC, THC-OH and 
THC-COOH in urine. Sample preparation and analytical separation and detection have been 
tested in order to get the best quantification results and the lowest sensitivity of the me-
thod. 
After the validation process, the objective will be to analyze “true” urine samples coming 
from doping control collection events. Negative and THC-COOH positive samples will be ana-
lyzed to quantify the 3 compounds of interest. 
Recently, herbal blends containing synthetic cannabinoid analogues have been intro-
duced on the drug market. These blends are illegally consumed as an alternative to cannabis. 
It is well known that the effects of these cannabinoids analogues are quite the same that the 
ones of THC and the abuse of such drugs would probably become a topic in the fight against 




In summary, the aims of this work will be: 
1. Develop, validate and implement a new GC-MS/MS analytical approach to quanti-
fy THC and its metabolites in urine. 
2. Quantify true samples that have already been found as adverse analytical finding 
with a THC-COOH concentration above the cut-off limit.  






4.1 General considerations about doping in sports 
Doping in sport can be defined as  
 
”a practice that consists in the absorption of specific substances or the practice of specific 
medical acts in order to artificially enhance one’s physical or mental capacities” [1].  
 
The use of different substances to improve sport performance is an old phenomenon; 
even the Greeks in the antique period used different potions and diets to enhance perfor-
mances. In 19th century, strychnine, caffeine, cocaine and alcohol were used to improve per-
formance in sports. In 1928, doping was banned by the International Association of Athletics 
Federations (IAAF). Other federations did the same, but since there were no detection me-
thods, the banning was not very effective. The first doping-tests were introduced in 1966, 
and drug-testing was introduced by most of the international sport federations by 1970. Un-
fortunately the tests were not always good enough; i.e. the use of anabolic steroids was for-
bidden in 1970, but a reliable test was not introduced until 1974. Another example is eryt-
hropoietin (EPO), which was introduced at the prohibited list inn in 1996, and a dependable 
test was not introduced until 2000 [2].  
The fight against doping is coordinated by WADA. Their goal is:  
 
“to promote, coordinate and monitor the fight against doping in sport in all its forms” 
[3].  
 
One important achievement from WADA is the World Anti-Doping Code (Code). This is a 
framework of anti-doping rules, policies and regulations to harmonize the fight against 
doping. Included in the code is the prohibition list, which is a list over all the substances and 
methods, banned from sports in- and out of competition. The different compounds are di-
vided in several classes which are forbidden either out-/and in-competition or only during 
competition (table 1). 
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 Out- / In-competition In-competition 
Classes 
S1. Anabolic steroids 
S2. Peptide hormones 







Table 1: Forbidden substances out-/and in-competition 
 
To be included on this list, a substance or a method needs to fulfill 2 of the following 3 
criteria [2]: 
a) Performance-enhancing 
b) Possible health risk for the athlete 
c) Damages the sports reputation.  
 
As cannabis fulfills all these criteria, it is included on this list. First, cannabis can, but only 
indirectly, improve performance. When consuming cannabis, the user may become 
euphoric, and anxiety may be reduced and sociability can be increased with a person who is 
particularly nervous before a game. The relaxing effect of cannabis and the increased feeling 
of wellbeing, can help the athlete to sleep more easily [4]. The sleeping quality can also be 
improved because THC can reduce alertness and help athletes to escape from social 
pressure [5]. Second, use of cannabis can be a health risk for the athlete; the user could end 
up dysphoric and paranoid, or, if used regularly, the user can become chronically sedated 
and socially detached [4]. This kind of use is also associated with development of diseases as 
schizophrenia and depression [6]. Third, use of cannabis in a sport can damage the 
reputation of the sport; the association of cannabis consumption and sport will prevent the 
athletes to appear as healthy idols. 
There are 35 anti-doping laboratories around the world, which daily screen for the pres-
ence of hundreds of drugs, metabolites and markers of prohibited substances in biological 
fluids. The analytical methods used in the anti-doping laboratories mainly rely on the use of 
chromatography combined with mass spectrometry (MS). 
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The anti doping laboratories have 3 main tasks that are  
1. Widen the range of doping substances and doping methods that can be detected.  
2. Prolong the interval of time between use of a doping substance/method and the time 
of possible detection. 
3. Increase reproducibility and robustness of the analytical results [7]. 
4.2 Cannabis 
4.2.1 Pharmacology and effects 
The psychoactive substance of cannabis is Δ-9-tetrahydrocannabinol (THC). This com-
pound binds to benzodiazepine, opioid and cannabinoid receptors. There are two types of 
cannabinoid receptors, cannabinoid 1 (CB1) and cannabinoid 2 (CB2)  [5]. CB1 are found in 
the brain, especially in regions involved in memory, cognition, anxiety, reward, sensory per-
ception, pain, endocrine function and motor coordination, and activation of CB1-receptors 
will then influence the properties controlled by these areas. CB2 receptors are present in the 
peripheral tissues [8], mainly in lymphoid tissues (i.e. tonsils, thymus and spleen). CB2-
receptors can also be found in the immune system, which may explain the immune depres-
sant effect of cannabis [9]. 
There is less knowledge with respect to the CB2-receptors than the CB1-receptor [9], thus 
the known effects of cannabis is mainly restricted to the effects in the brain. 
The main reason for consumption of cannabis is the euphoric effect. The user may be-
come careless, happy and relaxed, but could also end up dysphoric, anxious, psychotic, 
paranoid and in panic. Intake of cannabis can also be followed by depression or stress. If 
cannabis is consumed regularly, the user can become psychologically dependent, chronically 
sedated and social detached. Increasing the dose can give hallucinations and an alteration of 
the perception of reality [4, 8].  
Cannabis possesses a generalized central nervous system depressant effect, which leads 
to drowsiness towards the end of intoxication. Intake of cannabis decreases reaction time 
and causes memory problems. Concentration, driving skills and the ability to process com-
plex information are also impaired. These problems can last for several weeks, even if the 
user is not intoxicated [4, 8, 10]. 
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4.2.2 Pharmacokinetics and detection of THC in blood 
Cannabis is usually inhaled or ingested. Inhalation gives a faster absorption (plasma peak 
concentration is reached between 3 and 10 minutes) compared to ingestion (plasma peak 
concentration is reached after 1-2 hours). The amount absorbed is also reduced by a factor 
of 3 to 4 when ingested.  
After entering the circulation, the cannabinoids are rapidly distributed throughout the 
body. Because of the high fat solubility,  cannabinoids accumulate in fat tissues (i.e. liver, 
lung, spleen), and from there they are slowly released back into other body compartments 
[8] [11]. 
In blood 10 % of the cannabinoids are located in erythrocytes and the rest is found in 
plasma. Between 95 and 99 % of the drug is bound to plasma proteins, mainly lipoprotein 
and albumin. 
Many authors have investigated the concentrations of cannabinoids in blood. A study has 
shown that the plasma concentration of THC decreases rapidly, after smoking cigarettes con-
taining 16 and 34 mg cannabis. This caused average plasma concentrations of 84.3 ng/mL 
(range 50-129 ng/mL) and 162.2 ng/mL (range 76-267 ng/mL) for THC and THC-OH respec-
tively. The plasma concentration decreased rapidly to reach a value below 5 ng/mL after 3-4 
hrs. However, when the plasma concentrations of THC are decreasing, the amounts of me-
tabolites (11-OH-THC and THC-COOH) were increasing. The peak concentration for THC, THC-
OH and THC-COOH after start of smoking was observed after 8 min (range 6-10 min), 15 min 
(range 9-23 min) and 81 min (range 32-133 min) respectively [12]. 
6 hours after intravenous administration, pseudo equilibrium is reached between plasma 
and tissues, and THC is slowly released from tissues back into blood. At this point, the elimi-
nation starts to slow down, and the concentration in plasma of THC is < 2 ng/mL [13] [11]. 
Even though THC plasma concentration decreases rapidly, the terminal half-life is long, 
approximately 7 days. A complete elimination of a single dose may take up to 30 days [8]. 
The long terminal half-life is due to both accumulation of THC into lipophilic tissue, followed 
by a slow release back into blood and the binding of THC to plasma proteins [11, 14]. Thus 
the plasma half-life is dependent on the fat mass of the body but also to the frequency of 
use.  
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Different biological matrices (urine, blood i.e.) have been proposed for the detection of 
cannabis use. All have their limitations, and the choice of the appropriate sample is critical 
and depends on the context.  
For interpretation of acute effects after cannabis use, blood analysis is preferred [11, 15]. 
However, there are some problems with detection of cannabis in blood. Several cannabi-
noids are present in blood after marijuana exposure and their relative concentrations 
change over time. Also, the concentration of THC decreases so rapidly that the samples need 
to be collected within 2 hours after intake. To avoid this limitation THC-COOH plasma con-
centration is often measured. Blood sampling is also invasive and requires trained personnel, 
which is not the case when analyzing urine. 
Urine is still the preferred biological matrix for anti doping analyses even though blood is 
becoming more and more considered. Thus, cannabinoids have to be precisely detected and 
quantified in urine within anti doping laboratories. 
Only small amounts of the THC are excreted in the urine because of extensive metabolism 
[5] and reabsorption of THC in the kidneys. The most abundant urinary metabolite of THC is 
11-nor-Δ9-tetrahydrocannabinol (THC-COOH) [11]. THC-COOH is an inactive metabolite, and 
a result of the oxidation of the active metabolite 11-hydroxy-Δ9-tetrahydrocannabinol (THC-








 Figure 1:  Metabolism of THC via THC-OH to THC-COOH 
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THC-COOH, THC-OH and THC are excreted in urine mainly as a glucuronic acid conjugate 
[16] (Figure 2). There are mainly two analytical techniques to analyze these compounds. The 
first is through liquid chromatography (LC) which requires a simple sample preparation as 
the glucuronised compounds could be detected as such [17]. The second analytical method 
is via gas chromatography and involves a more complex sample preparation including a hy-
drolysis. 
THC-COOH is glucuronised by a ester-linkage, whereas an ether linkage attaches the glu-
curonide to THC and THC-OH (Figure 2) [18]. Thus THC-COOH can be submitted to basic hy-
drolysis, while THC and THC-OH must be hydrolyzed by enzymes. A study compared the yield 
of hydrolysis using β-glucuronidase produced from two different bacteria (Helix Pomata and 
Escherichia coli) and found that -glucuronidase from E.coli gave the best yield for THC and 















Figure 2: The glucuronide are linked to THC and 
THC-OH by an ether linkage and to THC-COOH by 
both an ester linkage and an ester linkage. The 
compounds are hydrolyzed to their non-












































There is a conflict in reported half-life for excretion of metabolites; some have reported 
an average urinary half-life of THC-COOH of about 45 to 60 hours, whereas other groups 
have reported wider time ranges [14]. 
Different factors such as frequency of cannabis use, body fat mass and degree of urine di-
lution can affect the concentration of THC metabolites in urine. Considering these factors, it 
is problematic to determine the time of last consumption [11].  
4.2.3 Passive versus active cannabis inhalation 
Cannabis can be consumed either by inhalation or ingestion. Ingestion is usually done by 
eating muffins, cakes etc. containing cannabis. Inhalation is the preferred route, usually by 
smoking a cannabis cigarette (a “joint”). The smoke from this cigarette will not only be in-
haled by the consumer, but also be distributed into the surrounding area exposing other 
people for inhalation of THC. Whether passive inhalation can give an adverse analytical find-
ing or not is highly debated, and several people with a positive cannabis sample have 
claimed passive inhalation [21, 22].  
Several studies have been performed to examine the detectability of passive inhalation 
[22-28], and in 2009, a meta analysis based on these studies (among others) concluded that 
it is unlikely to fail a doping-test due to unknown passive smoking of cannabis. The authors 
also indicated that urine samples positive for THC-COOH should be considered as an expres-
sion for active smoking [21]. However, the studies was performed several years ago (1977-
1996) using a THC content in the cannabis cigarettes (5-95 mg [21]), that might not reflect 
the situation today. 
In the 60`s and the 70`s, the normal THC content of cannabis was about 10 mg, but due to 
sophisticated breeding of cannabis plants, a THC-cigarette today could contain up to 150 mg, 
or 300 mg if laced with hashish oil, dependent on the sub specie of cannabis used [10]. This 
is confirmed by a report from USA, where the THC-content in cannabis increased from 4 to 
10 % within the time period 1983 to 2007 [29]. The situation might be different in Europe as 
confiscated cigarettes in 1998 had a THC content of 10 mg THC [30]. Anyhow, these findings 
are suggesting that the THC-content in cannabis products varies with the time period and 
location and needs to be considered in future studies of passive inhalation. 
As the urinary cannabinoid concentrations in urine are dependent on the amount inhaled, 
less abundant compounds such as THC and THC-OH might not be present in urine after pas-
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sive inhalation. Thus the application of these compounds in urine analysis can give informa-
tion about the consumption of cannabis; whether it is passive or active. 
4.3 Cannabis and doping 
4.3.1 Cannabis consumption in sport 
The direct effect of cannabis on sporting performance is negative. It is an ergolytic drug, 
which means it impairs motor, psychomotor and exercise performance [4]. The reduced mo-
tor performance includes impaired measurement of tracking ability, body-sway, hand-eye-
coordination, pursuit rotor performance, reaction time and physical strength among others 
[8]. Despite all these negative effects, the incidence of positive cases for cannabinoids is high 
[31] - it is actually on the top of the list of compounds detected by the anti-doping laborato-
ries accredited by WADA. Usually, the consumption of cannabis happens outside sports fa-
cilities, and is thereby not controlled by team coaches and/or doctors [4].  
4.3.2 The anti doping strategy for detection of cannabis 
According to the IOC and WADA, urine samples are considered as adverse analytical find-
ings if the total concentration of free and conjugated carboxy-THC in urine is above 15 
ng/mL when determined by GC-MS [4, 5]. The limit of 15 ng/mL is supposed to distinguish 
between passive smokers and active use. It also decreases the risk of a false positive result 
because of intake of contaminated food products [5].  
Unfortunately, there are some problems with this limit. Because of the long and diverse 
half-life of THC-COOH the strategy does not fully differentiate between use in-/and outside a 
competition, [4] [5, 13]. 
As several persons convicted for cannabis consumption claims that they have been pas-
sive exposed for cannabis [21, 22] and as the THC-content in cannabis have increased the 
last decades [10, 29], there is reason to believe that passive cannabis inhalation may give 
adverse analytical finding. 
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4.3.3 Approaches for determination of the time since cannabis consumption 
Concentrations of THC, THC-OH in blood and urine have been examined by several studies 
to estimate the time of last cannabis consumption [11-13, 32-34]. 
In 1992, a study developed two models for interpreting THC and THC-COOH concentra-
tions in blood to decide the time of cannabis consumption. The models managed to have a 
certain accuracy (90 % and 89 % for model I and model II respectively), but the confidence 
intervals allowed a duplication of the predicted time since consumption. Also, this models 
only took in account concentrations > 2 ng/mL, and only estimated consumption within the 
last 8 hours [12]. 
THC-concentration in urine has also been suggested as a biologic marker for recent can-
nabis use; urinary concentration above 2 ng/mL could be indicative of cannabis exposure 
within the last 5 h [13]. Also this study also only extended for 8 h after the drug administra-
tion.   
In 2009, a study measured THC, THC-OH and THC-COOH concentrations in urine in light 
cannabis smokers, who consumed cannabis cigarettes containing 70 mg THC. THC was de-
tected in concentrations of 0.1-1.3 ng/mL 2-8 hours after cannabis-consumption. The study 
also analyzed urine samples provided from LAD with a THC-COOH content >15 ng/mL, and 
found THC in concentrations up to 68.8 ng/mL. THC-OH was detectable in a somewhat high-
er concentrations, 0.1-14.4 ng/mL were detectable 2-72 hours after the consumption, and 
concentrations up to 213.6 ng/mL were detectable in urine samples provided from LAD [32]. 
Thus, both these compounds have potential as indicators for cannabis use in the context of 
doping. 
THC concentrations in blood and THC and THC-OH concentrations in urine among chronic 
smokers have also been examined. Both these studies concluded that these compounds are 
not good indicators for recent consumption in chronic users. The first study measured urine 
concentrations of THC, THC-OH and THC-COOH, and as THC and THC-OH was detectable 
within 72 hours (>2.5 ng/mL) and 4 days (40 ng/mL) respectively [33]. In the other study THC 
was detected in blood 7 days after the start of the study in concentrations between THC be-
tween 0.3-0.7 ng/mL. Cannabis was consumed at least 48 hours before study start [34], 
which support the results from [35]. However, these two studies are not directly relevant for 
anti-doping, as chronic cannabis consumption is not compatible with sports. 
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Another method has interpreted concentrations of THC, THC-OH and THC-COOH for de-
termining the time since cannabis use. This method is recommended for use in Germany for 
interpreting acute effects in cases of driving under influence [11]. However, as it is not likely 
that athletes are performing sports under the influence of cannabis, this method is neither 
applicable to doping.  
The dilution level of urine could alter the determination of THC-COOH-concentration. A 
THC-COOH/creatinine ratio can adjust for some of the variability of measured THC-COOH, 
and this can be used to obtain a more accurate determination of THC-COOH in urine. In 
1998, a study was performed to differentiate between recent and previous cannabis users 
based on calculations of THC-COOH/creatinine ratios, but the best prediction accuracy was 
85.4 %, with false positive and a false negative rate of 5.6 % and 7.4 % respectively [36]. 
A dihydroxy metabolite (8β,11-dihydroxy-THC) that is eliminated within 24 h in urine has 
been suggested as a possible marker for recent marijuana use [37]. However, another group 
was only able to detect this metabolite in one of 8 cannabis users. This user was a heavy 
cannabis smoker until 1 week before the beginning of the study [13].  
There are drawbacks with all these studies regarding the determination of the time of 
THC consumption. The determination of the THC/creatinine ratios gave a high positive rate, 
and there are problems with the detection of dihydroxy metabolite (8β,11-dihydroxy-THC). 
The interpretation of THC and/or THC-COOH and/or THC-OH concentrations is not applicable 
to chronic cannabis users, which however is of less relevance in sports.  
4.3.4 Analytical methods for detection of cannabis 
In screening of THC-COOH at LAD, THC-COOH-glucuronide is first hydrolyzed with β-
glucuronidase from E.coli. Then, a liquid-liquid extraction is performed using an organic sol-
vent. Finally, the extract is derivatized prior to analyses by GC-MS working in selective ion 
monitoring mode (SIM) [38]. 
For confirmation and quantification of THC-COOH at LAD, the urine sample is cleaned 
with a SPE prior to the injection on the GC-MS. THC-COOH is glucuronised in urine, so prior 
to the SPE the sample is subjected to basic hydrolysis with 11.8 N KOH at 60 °C in 20 mi-
nutes. Then the samples are mixed with acid, and extracted by a reversed phase solid phase 
extraction on a SPEC C18 column. The column is conditioned with organic solvent mixed with 
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an acid. After loading the sample, the column is washed with acid mixed with water. The 
analytes are eluted in a mix of organic solvents. Finally, the sample is evaporated and deriva-
tized before injected into the GC-MS, which is in SIM-mode. The GC-MS is scanning for the 
ions 371, 473 and 488, which is characteristic for THC-COOH-2TMS (11-nor-9-carboxy-delta-
9-tetrahydrocannabinol-2trimethylsilyl ether) and for the ions 380, 479 and 497, which is 
characteristic for THC-COOHd9-2TMS (11-nor-9-carboxy-delta9-tetrahydrocannabinol-d3-
2trimethylsilyl ether), the internal standard [3]. For MS-spectra of these two compounds, see 



















Figure 3b: MS-spectra of THC-COOHd9-2TMS. 
 
Several analytical methods for detection of THC, THC-OH and THC-COOH in urine are pub-
lished [13, 19, 32, 35, 37, 39]. These are different types of LLE extractions combined with GC-
MS [13, 19, 37] or LC-MS/MS [39] or a mixed mode solid phase extraction combined with 
GC-MS [32, 35]. Because of the extensively metabolism of THC and THC-OH it is desirable to 
go as low in concentrations as possible. Thus the method obtained from [32] was suitable for 
this thesis because it provides the best LLOQ and LOD, and the best accuracy compared to 
the other methods used.  
4.4 Sample preparation, detection and validation: theoretical points 
4.4.1 Sample preparation 
The sample preparations and detection methods used in this thesis will be discussed. Prior 
to analyzing a biological sample on i.e. a GC-MS, it is usually cleaned and concentrated [40].  
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Solid phase extraction 
In solid-phase-extraction, the sample is solved a liquid and loaded on a column with a sol-
id phase (sorbent). The analytes interacts with the sorbent and the liquid, and depending on 
the interactions, the analytes are either retained in the column or eluted with the liquid 
phase. The sorbent is usually made of silica, where functional groups are attached to optim-
ize the interactions with the analytes. Different functional groups can be chosen, according 
to the properties of the analytes.  
There are 4 different types of solid phase extractions: 
1. reversed phase extraction, extract non-polar analytes from a water-based solution 
2. ion-exchange extraction, extract ionic analytes from a water-based solution 
3. normal phase extraction, extract polar analytes from a organic solution 
4. mixed-mode extraction, extract analytes with both hydrophobic and ionic properties 
The extraction procedure is common for all the types, and can be divided into four steps: 
conditioning, sample loading, washing and eluting (Figure 4).  
The conditioning will activate and prepare the functional groups, to allow the interaction 
between the analytes and the solid-phase. Then, the sample is loaded on the column. The 
purpose of the washing procedure is to remove contaminants that have been retained on 
the column without removing the analytes. The last step should allow the elution of the ana-









         Figure 4: The extraction procedure in solid-phase extraction (inspired from [40] 
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 Reversed phase SPE is used to clean up a non-polar analytes from aqueous solutions. The 
functional groups are hydrophobic, and so are the interactions between the analytes and the 
sorbent. The bigger the functional groups are, the more hydrophobic is the sorbent. Exam-
ples of sorbents are octadecyl (C18), octyl (C8), ethyl (C2) and cyclohexyl.  
To promote the hydrophobic interactions between the analytes and the sorbent, the ana-
lytes are dissolved in a hydrophilic matrix, i.e. urine. The pH in the sample solution and the 
washing solution favor the non-ionic form of the analytes, with the purpose of increasing the 
interactions between analytes and sorbent. This will promote retention of the analytes while 
some contaminants are washed out. The elution solution is a organic solvent which will 
break the interactions between the analytes and the sorbent [40].  
In mixed-mode extraction, the sorbent contains both hydrophobic and ionizable groups, 
which makes it possible to retain the analytes by hydrophobic interactions, ion exchange 
interactions and hydrophilic interactions. The column is usually conditioned with methanol 
and water. The pH can be adjusted in the conditioning step, the sample solution and the 
washing step, to promote the ionic interactions between analytes and sorbent. Since the 
analytes are retained by stronger interactions than in the reversed phase extraction, the 
sample can be washed more thoroughly, and the extract will usually be cleaner compared to 
a reversed phase SPE extract. The analytes is eluted with an elution solution that breaks all 
the interaction between the sorbent and the analytes [40].  
Liquid-liquid extraction  
In this type of extraction, the analytes are transferred from an aqueous phase to an or-
ganic liquid. The partition of the analytes between these two liquids is given by the partition 
coefficient, K, which should be high for the analytes and low for the contaminants. 
 
K = [A]Organic/[A]aq 
 
[A]Organic is the concentration of the compound in the organic solution, while 
[A]aq is the concentration of the compound in the aquatic solution. 
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To get this partition coefficient as high as possible for the analyte, one have to consider 
the pH in the aqueous sample and the choice of the organic solvent. Regarding the pH in the 
aqueous sample, this should be adjusted favor the non-ionized form of the analyte to in-
crease the solubility in the organic phase.  
The organic solvent needs to be immiscible with water, and should have the same chemi-
cal properties as the analytes regarding polarity. If the analyte is an acid, the solvent should 
be proton accepting, and the opposite if the analytes is a base [41].  
To increase the recovery of a LLE multiple extractions or increasing amounts of solvents 
could be used. If 83 % of an analyte is transferred to the organic solvent with one extraction, 
another extraction will increase the recovery to 97 %. The recovery can also be increased by 
increasing the amount of organic solvent, but these solvents are usually toxic and should be 
used in a small amount as possible.  
Some contaminants will also be transferred to the organic phase after LLE. To increase 
the sample clean-up, a back-extraction can be performed with an aqueous solution having a 
pH allowing ionization of the analytes, which makes the analytes more soluble in the 
aqueous solution [40]. 
4.4.2 Gas chromatography 
A GC separates the analytes in a sample extract and consists of an injector, a carrier gas, a 
reduction valve, a column and a detector.  
The principle of GC is separation of the compounds in a sample due to interactions be-
tween a gaseous mobile phase and a stationary phase. The compounds are dissolved in an 
organic solvent and injected in the injector where it evaporates immediately. The most 
common injectors are split and split less injectors. In split less injections, the whole amount 
of injected sample are transmitted to the column, which makes it more suitable for anti dop-
ing analysis, as the concentrations of the doping agents in biologic matrices usually are low. 
The mobile phase, a carrier gas, will transport the sample from the injector into the column 
where the analytes are partitioned between a stationary phase and the gaseous mobile 
phase. Hence the compounds are retained at the stationary phase in different degrees and 
separated. The partition of the analytes between the two phases depends on the volatility of 
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the analyte, the column temperature, the properties of the stationary phase (polarity, thick-
ness etc.), and on the speed of the carrier gas.  
The analytes are derivatized before they are injected in the GC to make them more 
volatile and stable at high temperatures. In a derivatization process, these polar groups are 
remade to non-polar groups. The derivatization process used in this thesis was silylation, 
which is suited for compounds containing functional groups as OH, COOH, NH and NH2. The 
hydrogen of these groups are replaced by a trimethylsilyl(TMS)-group [40]. 
4.4.3 Mass spectrometry 
The mass-spectrometer is measuring masses. It cannot detect neutral molecules, only 
ions, thus it is necessary with an ion source which ionizes the compounds [42]. 
There are different ways of ionizing the analytes, but as only electron ionization (EI) was 
used, only this will be discussed here. EI is a common type of ionization in combination with 
GC-MS. In EI, the neutral molecules are guided into an ionization chamber in vacuum which 
contains an anode and a filament. The anode has a positive charge, and current is added to 
the filament. Between the filament and the anode there is a beam of electrons with energy 
of usually 70 eV, se Figure 5. When an electron with this energy impacts a molecule, an 












Figure 5: Sketch of ionization chamber in electron ionisation (Inspired by [42]. 
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The molecule left will then have a positive charge and an unpaired electron, this is called 
the molecule ion (M·+). The mass will be the same, since the mass of the ejected electron is 
negligible compared to the remaining mass of protons plus neutrons. 
 
M + e- → M·+ + 2e- 
M = unionized molecule 
M·+ = molecular ion 
e- = electron 
 
The molecule ion is unstable, and most of the molecule ions will be fragmented into 
smaller pieces (fragment ions). The ionization process makes a fragmentation pattern which 
is typical for the molecule, and this pattern is often available in databases. These databases 
can be used for identification of the molecule [40, 43]. After they are ionized, the analytes 
are guided into a mass-separator.  
The mass-analyzer is usually a quadrupole, which separates the ions according to their 
mass-to-charge-ratio (m/z). The quadrupole consists of 4 parallel rods, divided in two pairs, 
in a electrical field [40]. The pairs are charged, either positive or negative, and this charge 
changes from positive to negative (and back again) with a given frequency. The ions 
produced in the ion source travel along the longitudinal axis of the rods, and are attracted to 
the rods depending on their charge; positive charged ions are attracted to the negative 
charged rods, and opposite. A certain combination of charge and frequency allows 
preselected ions with a certain m/z ratio (SIM) or within a certain m/z-ratio range (scan) to 
travel through the filter [42]. These data will be transferred to a computer and treated 
electronically [40]. 
The different scan-opportunities are increased when using a mass-analyzer with three 
quadrupoles, a triple stage quadrupole (TSQ). The analysing quadrupoles are called Q1 and 
Q2, and they are separated by q, a collision cell (Figure 6). Q (the collision cell) fragments the 
ions escaping from Q1 before they enter Q2. The detector is placed after Q2 [44]. 
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Figure 6: The quadrupoles in MS/MS: Q1 and Q2, separated by q. Reprinted with permission from Terje 
Vasskog. 
 
Both Q1 and Q2 can be set in both SIM and Scan-mode [42]. This gives a wider range of 
scan-opportunities when compared to a regular MS-machine; product scan, parent scan and 
MRM (multiple reaction monitoring). 
Product scan and MRM were used in this project. In a production scan (see Figure 7), the 
Q1 is set in SIM-mode at a selected ion and the Q2 is set in SCAN-mode. The selected ion is 
fragmented in q. The ions produced in q are further directed to Q2. Since Q2 is in Scan mode 
all ions produced in q are recorded. From this MS/MS spectrum abundant ions are candi-
dates for analysis based on the use of MRM [42, 44] 
Figure 7: Product scan. All the product ions enter the Q1. Q1 choose one of these, which is fragmented in 
q. All the fragments from q pass the Q2, and are detected. This is one of the steps in setting up a MRM-
method. The figure is inspired of [42]. 
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Figure 8: MRM-scan. All the ions fragmented in the ion source enter the Q1. In the first quadrupole, Q1, 
only the product ion is passing through and fragmented in q. The fragmented ions enter Q2, where only 
the selected fragment ions are passing through and detected. The figure is inspired of [42]. 
 
A MRM-method is more specific than a SIM-method. The risk for another compound hav-
ing the same transition is reduced compared to having the same ion from the ion source. 
 The ability to detect small amounts is obtained, since the noise is reduced compared to a 
SIM-scan, and this give a higher signal to noise ratio [42]. 
As the urine concentrations of THC could be quite low (urine concentration >2ng/mL is 
indicative of cannabis exposure within the last 5 h [13]), there is need for a specific and sen-
sitive detection method.  
4.4.4 Validation procedure 
Validation can be defined as: 
 
“Establishing documented evidence which provides a high degree of assurance that a specific 
process will consistently produce a product meeting its pre-determined specifications and 
quality attributes”[45] 
 
The validation procedure documents that the method is fitted for its purpose.  













Lower limit of detection (LOD) 
LOD is the lowest concentration where an analyte can be detected. It can be calculated by 
dividing the area of the signal on the area of the noise, and this ratio (signal to noise ratio, 
S/N) should be ≥ 3 [40]. The signal of the noise is the height of the baseline. 
 
Lowest limit of quantification (LLOQ) 
LLOQ is the lowest concentration where an analyte can be quantified. It can be calculated 
in the same way as LOD, but the S/N should be ≥ 10 [40].  
If the signal to noise ratio is low, it is difficult to say how much of the signal that is due to 
the analyte, and how much that is due to the matrix, thus a reliable quantification would be 
difficult. There are no requirements for the LLOQ or LOD value in doping analysis, but the 
value should fit the purpose. 
 
Upper limit of quantification (ULOQ) 
ULOQ, upper limit of quantification, is the highest concentration where the analyte can 
be quantified, before having a saturated signal. At this point, the calibration curve will go 
from being linear to parabolic. 
 
Linearity 
Linearity is the ability of the method to give a linear calibration curve in a given concen-
tration range. The ratio is given by the response of the analyte which is divided by the re-
sponse of the internal standard, and allows a plot at different concentrations. A calibration 
curve is then obtained, and allows the calculation of urine of an unknown sample. The linear-
ity of the equation is described by R, the regression coefficient [40]. R2 should be as close to 
1 as possible, but a value above 0.995 is satisfying.  
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Specificity 
The specificity is the ability of the method to detect and quantify the analyte in presence 
of contaminations in the sample. The signal of the analyte should not be interfered by these. 
The specificity of the method can be tested by analyzing negative samples from 6 different 
subjects, and 3 samples per subject are analyzed. The signals in the negative urines are ex-
amined for interfering signals.    
 
Range 
This is the interval between the lower and the upper concentration where the method 
can quantify the analyte with a suitable accuracy, precision and linearity. 
 
Precision 
This parameter describes the diversity of the results, and are expressed by a relative 
standard-deviation (RSD), which is the standard deviation of the results divided by the mean 
value of the same results, and multiplied by 100. A low RSD indicates a good precision. 6 
samples for 3 concentrations in the range are analyzed. The analyzed concentrations should 
reflect the concentration range.  
 
Accuracy 
Accuracy represents the closeness between the theoretical value and the calculated val-
ue. Hence, this parameter considers the uncertainty and the precision of the method. The 
uncertainty can be determined by calculation of the theoretical values in the sample by us-
ing a calibration curve. The calculated- and the theoretical value are plotted in a curve. The 
linearity and the slope of the curve demonstrate the correlationship between these values; a 
linear curve with a slope of 1 suggests a good correlation between these.  
 
Robustness 
The robustness is an assessment on the ability of a method to stay unaffected by minor 
changes in the procedure, i.e. e. small variations in pH. This is to make sure that the analysis 
is not affected by variations that might occur in a sample preparation [40].  
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5 Material and methods 
5.1 Chemical and reagents 
THC(δ-9-tetrahydrocannabinol,(−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-
tetrahydro-6H-benzo[c]chromen-1-ol)1 mg/mL in ethanol, THCd3 (δ-9-tetrahydrocannabinol-
d3, (−)-(6aR,10aR)-6,6,9-trimethyl-3-([5`5`5`-trideuteropentyl])-6a,7,8,10a-tetrahydro-6H-
benzo[c]chromen-1-ol) 0,1 mg/mL in methanol, THC-OH(11-hydroxy-δ9-
tetrahydrocannabinol, 6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,8,10a-
tetrahydro-6H benzo[c]chromen-1-ol) 0,1mg/mL in methanol,THC-OHd3(11-hydroxy-δ9-
tetrahydrocannabinol-d3,6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-([5`5`5`-
trideuteropentyl])-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol-d3) 0,1 mg/mL in metha-
nol and THC-COOH (11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid, 1-hydroxy-6,6-
dimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-9-carboxylicacid) 0,1 mg/mL 
were purchased from Lipomed (Arlesheim, Switzerland). THC-COOHd3 (11-nor-delta(9)-
tetrahydrocannabinol-9-carboxylicacid-d3,1-hydroxy-6,6-dimethyl-3-([5`5`5`-
trideuteropentyl])-6a,7,8,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid)  0,1 mg/mL in 
methanol and THC-COOHd9 (11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid-d9, 1-
hydroxy-6,6-di[trideuterateromethy]-3-([5`5`5`-trideuteropentyl])-6a,7,8,10a-
tetrahydrobenzo[c]chromene-9-carboxylic acid) 0,1 mg/mL in methanol were purchased 
from Cerillant (Round Rock, TX, USA). Phosphoric acid 85 %, K2HPO2 (dipotassium hydrogen 
phosphate) (>98 %), β-glucuronidase type IX-A, 1`660`000 units/g solid from Escherichia coli 
and sodium chloride (HCl) 37 % fuming was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Methanol (99.9 %), KH2PO4 (potassium dihydrogen phosphate) (99.5-100.5 %) and 
acetic acid glacial (100 %) was purchased from Merck (Damstadt, Germany). BSTFA + TMCS 
99:1, purchased from Sigma Aldrich (Buchs, Switzerland). β-glucuronidase type K12 140 
U/mg was purchased from Roche Diagnostics GmbH (Mannheim, Germany). Acetonitrile 
(AcN) (99.97%) was purchased from Biosolve (Valkenswaad Netherlands). Sodiumhydroxide 
(NaOH) pellets (>99 %) was purchased from VWR International (Leuven Belgium). Hexane 
(99.78 %) and potassium hydroxide (KOH) pellets > 85 %was purchased from Acros Organics 
(Geel, Belgium). Etyl acetate (99.8 %) was purchased from Panreac (Barcelona, Spain) and 
from VWR (Fontenay-sous-Bois, France). Ultrapure water was produced by a Milli-Q gradient 
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A10 water purification system with a Q-Gard 2 and a Quantum EX Ultrapure organix car-

















Molecular weight: 314.5 g/mol Molecular weight: 317.5 g/mol 
Monoisotopic mass: 314.2 u Monoisotopic mass: 371.2 u 
pKa: 9.6 pKa: 9.6 


















Molecular weight: 330.5g/mol Molecular weight: 333.5 g/mol 
Monoisotopic mass: 330.2 u Monoisotopic mass: 333.2 u 
pKa: 9.6  pKa: 9.6 



















Molecular weight: 344.5g/mol Molecular weight: 347.5g/mol 
Monoisotopic mass: 344.2 u Monoisotopic mass: 347.2 u 
pKa: 4.6 pKa: 4.6 
Average logP: 5.30 (±0.82) Average logP: 5.30 (±0.82) 
 
Figure 9: Structure, molecular weights (MW) and pKa-values for the investigated compounds. The pKa-values 
and the logP are predicted values [46, 47] 
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5.2 Buffers and solutions 




THC was obtained in a concentration of 1 μg/mL in ethanol, while THC-d3, THC-OH, THC-
OHd3, THC-COOH and THC-COOHd3 were obtained in a concentration of 1 μg/mL in metha-
nol for the development of MRM-method. 
For development of the sample preparation, a mix of THC, THC-OH and THC-COOH were 
obtained in a concentration of 1 μg/mL (standard solution), and a mix of THCd3, THC-OHd3 
and THC-COOHd3 were obtained in the same concentration. 
For the method validation mix of THC, THC-OH and THC-COOH were obtained in concen-
trations of 0.01 μg/mL, 0.1 μg/mL, 1 μg/mL and 10 μg/mL. 
THC-COOHd9 was obtained in a concentration of 1 µg/ml in methanol. 
All the stock solutions were stored at -20°C.  
 
Phosphate buffer, pH 6.8 
4.33 g K2HPO4 and 3.42 g KH2PO4 were transferred to a beaker, and about 400 mL MilliQ 
water was added. The pH was adjusted to 6.8 with 0.1 M NaOH. The solution was trans-
ferred to a 500 mL cylinder and MilliQ-water was added up to 500 ml. The pH was measured, 
and adjusted to 6.8 with phosphoric acid 85%. The solution was stored at 5°C. 
 
Acetic acid solution, 0.1 M 
5.725 ml acetic acid pure was transferred to a 1000 mL flask, and MilliQ-water was added 
up to the mark. The solution was stored at 5°C. 
 
Hydrochloric acid solution, 0.1 M 
5 ml 37 % HCl fuming, was transferred to a 500 mL flask, and MilliQ water was added up 
to the mark. The solution was stored at 5°C. 
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β-glucuronidase solution, 10`000 UI/200 μg 
603.7 mg β-glucuronidase from E.coli, type IX-A, 1`660`000 units/g solid, was transferred 
to a 20 mL flask, and dissolved in 20 mL phosphate buffer, pH 6.8. Aliquots of 1 ml were then 
in Eppendorf tubes transferred and stored at -20°C. 
 
HCl 0.1 M/AcN 70/30 
30 mL AcN was transferred to a 100 mL flask. The flask was filled with HCl 0.1 M up to the 
mark, and then shaked. Stored at 5°C. 
 
Hexane/ethyl acetate 80/20 
20 mL ethyl acetate was transferred to a 100 mL flask. The flask was filled with hexane up 
to the mark and shaked. Stored at 5°C. 
5.3 Sample preparation 
Spiking of urine 
The final volumes used for spiking urine was: 1 mL urine samples, 200 μl phosphate buffer 
pH 6.8, 50 μl internal standards (1µg/ml) and 165 μl β-glucuronidase solution, type IX-A 
(10`000 U/200 μl).  
 
Derivatization 
After sample clean up the samples extract was evaporated under nitrogen, and resolved 
in 25 μl AcN mixed with 20 μl BSTFA:TMCS 99:1. The sample extract was derivatized at 85°C 
for 30 minutes, and 2 μl was injected in the GC-TSQ. When preparing samples for quantifica-
tion in urine samples, the derivatization procedure was changed to 50 μl MSTFA, 90°C, 20 
minutes.  
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Mixed mode SPE  
Obtained from [32]  
The extraction procedure for the mixed mode SPE can be found in table 2. 
Condition Load sample Wash Elute 
Methanol: 3mL 
1.4 mL 
MilliQ water: 2 mL 
Hexane:ethyl acetate, 80/20:  
3 mL 
MilliQ water 3 mL 
HCl 0.1M/AcN: 2mL 
Acetic acid 0.1 M: 2 mL 
Table 2: The extraction procedure for the mixed mode SPE 
 
Reversed phase SPE  
Obtained from [38]. 
The extraction procedure for the reversed phase SPE can be found in table 3. 
Condition Load sample Wash Elute 
Acetic acid 0.1 M in 
methanol: 
 200 µl 
1.4 mL 
Acetic acid 20 % in wa-
ter: 1 mL 
Hexane:ethylacetate 
75/25: 
2 × 500 µl Dry for 20 minutes 
Table 3: The extraction procedure for the reversed phase SPE. 
 
LLE  
Obtained from [48] and adjusted. 
The sample was acidified with 1.5 mL acetic acid pure.  
The LLE was performed with 2 × 3.5 mL hexane:ethyl acetate 90:10. 
5.4 Instrumentation 
Columns for solid phase extraction 
UCT Clean Screen CSTHC203, octyl and aminopropyl, 200 mg/3mL solid phase extraction 
(SPE) columns were purchased by Laubscher Labs (Miecourt, Switzerland) and the Baker-
bond C18 30 mg/3mL SPE columns were purchased by Varian (Lake Forest, CA, USA).  
 
GC-TSQ 
The GC-TSQ system was composed of a Trace GC ultra Thermo Scientific coupled to a TSQ 
Quantum MS (Thermo) purchased from Brechbühler AG, (Schlieren, Switzerland) equipped 
with a Agilent 100-2000 (column material: HP-1; methyl polysiloxane, 17 x 0,2 mm I.D., 0.11 
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μm film thickness) from J&W Scientific (Böckten, Switzerland). 2 μl of the samples was in-
jected in split mode, with a Triplus Autosampler Thermo Scientific purchased from 
Brechbühler AG (Schlieren, Switzerland). The injection was later changed to split less mode. 
The injector temperature was 260 °C. The temperature of the transfer line was 280 °C and 
the temperature of the source was 250°C. The carrier gas used was helium, with a flow of 1.5 
mL/min in constant flow mode. The ramping of the oven temperature was as follow: 150°C 
at 1 minute to 280°C at 20°C/minute and held at this temperature for 280°C in 5 minutes. 
The ionization mode was in positive mode, and the ionization potential in the ionization 
source was 70 V, and the emission current was 250 µm. The dwell time was 20 ms.The colli-
sion gas used was argon. 
Some experiments were also performed on the machine above, but with another column, 
Zebron 5MS column (colunmmaterial: 5 % polysilarylene/95 % Polydimethylsiloxane, 30 m x 
0,25 mm I.D., 0,25 μ film thickness) from Brechbühler (Schlieren, Switzerland). The rest of 
the condition was held the same as above. 
 
GC-MS  
One GC-MS system was composed of Agilent 6890 Series GC-system from Agilent 
(Waldbronn, Germany) equipped with a Zebron 5 MS column (columnmaterial: 5% Polysila-
rylene/95 % Polydimethylsiloxane, 30 m x 0,25 mm I.D., 0,25 μ film thickness) from 
Brechbühler (Böckten, Switzerland). The GC was coupled to an Agilent 5973 detector 
(Waldbronn, Germany).  
Helium was used as a carrier gas, with a flow of 1.1 mL/min in constant flow mode. 
The ramping of the oven temperature was as follow: 150°C at 1 minute, to 280°C at 
20°C/minute. 1 μl of the samples was injected in split less mode at 260°C with a Hewlett 
Packard 7683 series injector (Walbronn, Germany). The ionization potential was 70 eV and 
the emission current was 270 µm. The interphase temperature was 280°C, the source tem-
perature was 200°C and the quadrupole temperature was 150°C. The dwell time was 50 ms. 
The temperature and column was adjusted during the project to improve the method. The 














Ion 303 371 371 
389 374 374 Ion 371 403 473 
Ion 386 474 488 
Table 4: The ions used in GC-MS, SIM-mode. 3 ions per analyte were chosen in order to be able to have a 
quality control for the analysis.   
 
5.5 Specificity 
The specificity of the signal was tested by spiking 6 different male and 6 different female 
cannabis negative urines with β-glucuronidase, phosphate buffer and 50 μl methanolic stan-
dard of THC-COOHd9 (1 μg/mL), which were used as internal standard. 3 parallel urines per 
subject were spiked. One negative urine from one of these volunteers was spiked with 50 μl 
standards (1 μg/mL), 50 μl internal standards (1 μg/mL), phosphate buffer and β-
glucuronidase. 
The samples were hydrolyzed, extracted with the mixed mode SPE, evaporated, deriva-
tized and injected. The signals in the negative urines were compared with the signal in urine 
spiked with analytes and internal standards. 
The specificity test was first performed on GC-MS in SIM-mode. To improve the specifici-
ty, the temperature and the column ramping were adjusted. The experiment was later re-
done using the GC-TSQ in MRM-mode.   
5.6 Linearity and detection limits 
6 different urines, 3 males and 3 females, were spiked with different amount of the 
standards to a concentration in urine of 0.1, 0.5, 1, 3, 5, 7, 9, 10, 50, 100, 500 and 1000 
ng/mL of THC, THC-OH and THC-COOH. To obtain the same amount of liquid in all the 
samples, the standard solutions were evaporated before adding urine, buffer, enzyme-
solution and internal standards. 
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6 Results and discussion 
During this thesis a GC-TSQ method has been developed to detect THC, THC-OH and THC-
COOH. Specificity, selectivity and linearity have been tested as well as the sample prepara-
tion. 
6.1 Method development 
The aim was to develop and validate an analytical method for detection and quantifica-
tion of THC, THC-OH and THC-COOH and one method for the cannabinoid analogues. Several 
technical problems hindered the progress of the project and therefore only sample prepara-
tion, specificity, selectivity and linearity for THC, THC-OH and THC-COOH have been studied. 
6.1.1 Conditions of hydrolysis 
THC, THC-OH, THC-COOH are all excreted mainly as glucuronide conjugates and should be 
hydrolyzed before they are injected in a GC [16]. Based on previous literature, only β-
glucuronidase from E.coli was used [19]. A few parameters are important to optimize the 
conditions of hydrolysis. Three of them have been tested, which are the amount of enzyme, 
the time of hydrolysis and the temperature. 
For investigation of the quantity of β-glucuronidase, a solution of β-glucuronidase type 
K12 of 140 U/mg (corresponding to at least 140 U/mL) was added in different quantities to 1 
mL urine samples, previously quantified for THC-COOH (941 ng/mL, previously quantified at 
GC-MS). The quantities added were: 50 μl, 100 μl, 500 μl and 1 mL. Phosphate buffer inter-
nal standards were added to all the samples and the pH was between 6 and 7. Each sample 
was extracted in triplicate and hydrolyzed at 37°C for 16 hours.  
As a reference,  1 mL urine previously quantified for THC-COOH (941 ng/ml, previously 
quantified GC-MS) was spiked with 125 µl KOH and internal standard, and subjected to basic 
hydrolysis at 60°C for 2 min [3]. The sample was neutralized with 450 µl acetic acid before 
the extraction. 
All the samples were extracted with the reversed phase SPE, evaporated and derivatized. 
2 μl of all the samples were injected in the GC-TSQ system in MRM-mode. 
The ratios between the peak area of the transitions chosen for quantification of the ana-
lyte and the peak area of the transition chosen for quantification of the internal standard 
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were calculated for each quantity of β-glucuronidase solution (table 5). The chromatograms 
for the optimal quantity of β-glucuronidase and for the basic hydrolysis can be seen in figure 
10. 
Figure 10: Chromatogram from GC-TSQ in MRM-mode, of the TMS-derivates of the compounds subjected 
to hydrolysis with 500 µl β-glucuronidase 140 ug/mL at 37°C for 16 hours (6 upper chromatograms) and of 




Table 5: The table shows the ratios of peak area for the TMS-derivates of the analytes/peak area for TMS-
derivates of internal standard after addition of different quantities β-glucuronidase. The areas are obtained 
from figure 10. 
 
A high ratio indicates an effective hydrolysis. Hence, the results in table 5 indicate that 
500 μl is a suitable quantity of the enzyme solution as this is the best quantity for THC-OH-
glucuronide and THC-COOH-glucuronide (the ratio is 10.0 and 41.1 respectively). For THC, 
the different quantities are almost not affecting the ratio. 
The sample subjected to basic hydrolysis in this experiment confirmed this result: the 
peak area ratio of THC-COOH-2TMS/THC-COOHd3-2TMS in this sample was set to 100 %, 
and compared with the area ratio THC-COOH-2TMS/THC-COOHd3-2TMS from table 5. The 
highest percentage (127.3 %) indicates the most efficient hydrolysis regarding THC-COOH-



















32.3 39.6 40.6 21.1 38.7 
In percent 100.0 122.6 125.7 127.3 120.0 
Table 6: Ratios of the peak area of THC-COOH-2TMS/peak area THC-COOHd3-2TMS for basic hydrolysis and 
for enzymatic hydrolysis when different quantites of β-glucuronidase were added. The ratios of THC-COOH-
2TMS/THC-COOHd3-2TMS subjected to enzymatic hydrolysis are calculated as a percentage of the ratio THC-
COOH-2TMS/THC-COOHd3-2TMS subjected to basic hydrolysis. 
  Quantity β-glucuronidase (µl) 





THC-TMS/THCd3-TMS 0.4 0.5 0.5 0.5 
THC-OH-2TMS/ 
THC-OHd3-2TMS 
3.1 5.7 10.0 9.8 
THC-COOH-2TMS/ 
THC-COOHd3-2TMS 
39.6 40.6 41.1 38.7 
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The results also indicate that THC-COOH-glucuronide is easier hydrolyzed compared to 
the two other analytes. THC-COOH-glucuronide can also be subjected to basic hydrolysis 
because of the ester linked glucuronide, but THC-glucuronide and THC-OH-glucuronide can-
not undergo this type of hydrolysis, because of the glucuronide attached to those analytes 
are ether-linked [18]. 
Unfortunately, the costs would be too high if the optimal quantity (500 μl) of the enzyme 
solution of β-glucuronidase K-12 should be used in this project. Therefore, a new solution of 
β-glucuronidase type IX-A was made (10`000 U/200 μl). Different amounts, 50 μl, 100 μl, 150 
μl, 200 μl and 300 μl of the latter enzyme solution were added to 1 mL negative urine with 
phosphate buffer and the internal standard. These samples were supposed to be extracted 
with the solid phase extraction, but this analysis was not performed because the enzyme 
solution clogged the reversed phase SPE column. 
To spare some time in the project and based on previous publications [32, 35, 37], it was 
decided to use a volume of 165 μl (8250 U) per mL urine. Even if the usual amount of en-
zyme used is between 4000 and 5000 U/mL of urine a higher concentration would not affect 
the hydrolysis yield [19] 
To determine the time of hydrolysis a urine sample previously quantified for THC-COOH 
(941 ng/mL) at GC-MS was used. β-glucuronidase, phosphate buffer and internal standard 
were added to the sample and different time and temperatures were tested for hydrolysis 
(1h at 50°C, 1.3h at 50°C, 2h at 50°C and 16h at 37°C). Three samples per condition were 
extracted with the mixed mode SPE, derivatized and 2 μl injected in the GC-TSQ. As the in-
tensity of the signal decreased abnormally between 5 injections the results obtained from 
this analysis were not conclusive. The same samples were injected in a GC-MS. 
In order to define the m/z ions for the SIM GC-MS method, the MS-spectra for the com-
pounds were obtained by injecting methanolic standards of the analytes and the d3-internal 
standards in scan-mode (12a, b, c and 13a, b, c). 
To evaluate the different hydrolysis conditions, the peak area of the TMS-derivate of the 
analytes was divided by the peak area of the TMS-derivate of the appropriate internal stan-
dard and the mean value of the ratio obtained from the three samples was calculated. The 
highest mean value indicates the most efficient hydrolysis (Table 7). For THC-glucuronide 
and THC-COOH-glucuronide the hydrolysis is barely more consistent at 50°C for 2h, followed 
by 37°C for 16h, the ratios are almost equal for these two conditions. Regarding the THC-OH-
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glucuronide, the hydrolysis is clearly better at 37°C for 16 hours. Since the analytes should 
be quantified and not only detected, it is important to get the highest amount of compound 
analyzed, so the hydrolysis at 37°C for 16 hours was chosen. 
 
Table 7: The mean value of the ratio between the peak area for the TMS-derivates of the analytes and the 
peak area for TMS-derivates of the internal standards at different hydrolysis- times and temperatures. 











Ion 371 385 371 371 473 488 
Β-gluc 1h at 50°C 1.1 0.4 2.9 21.0 11.5 9.0 
β-gluc 1.3h at 50°C 1.2 0.5 3.9 21.7 12.2 9.5 
Β-gluc 2h at 50°C 1.2 0.5 4.4 22.0 12.4 9.8 
Β-gluc 16h at 37°C 1.2 0.5 6.0 21.6 12.0 9.4 
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Figure 12a: MS-spectra of THC-TMS after injecting methanolic standards. 
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 Figure 12b: MS-spectra of THC-OH-2TMS after injecting methanolic standards. 
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6.1.2 Sample preparation 
Three different sample preparations were tested, a mixed mode SPE, a LLE and a LLE 
combined with the reversed phase SPE. In the combined extraction the extracts from the LLE 
were dissolved in 1 mL of MilliQ water and acidified with 200 µl acetic acid pure. Two extrac-
tions were performed per sample preparation and the extractions were evaporated, deriva-
tized and injected in GC-TSQ in MRM-mode. 
Many of the experiments gave no results. The decision of sample preparation was based 
on noise in the chromatogram, practical reasons, literature review and analytical considera-
tions. The LLE was excluded because of noise in the chromatogram (Figure 14), and the re-
versed phase SPE was excluded due to clogging of the column. The combination of these two 
was a complicated and time-consuming extraction; hence this is not a suited sample prepa-
ration for a screening procedure. As the mixed mode sample preparation had a low LOD, 
LLOQ and a good accuracy, it is well suited for the purpose of this thesis. The mixed mode 
sample preparation utilizes a number of interactions when retaining the analyte on the col-
umn, thus the sample are washed more thoroughly.  
In this case, the analytes are very hydrophobic (logP are 5.30-6.55) with some polar, and 
in the case of THC-COOH ionizable, properties. The mixed mode extraction utilizes all these 
properties of the analytes; the octyl group will interact with the hydrophobic part of the mo-
lecule, while the aminopropyl group will interact with the hydrophilic and ionizable parts. 
Thus, the sample can be washed with both water and AcN. In LLE and reversed phase SPE 
the analytes are extracted or retained due to hydrophobic interaction, and the sample are 
not cleaned that thoroughly.  
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Figure 14: GC-TSQ chromatogram, MRM-mode, of urine samples spiked with standards and internal stan-
dards and extracted with LLE. In addition to noise in some of the chromatograms, there is an interfering sig-





6.1.3 MRM method development 
The retention time and the mass-spectra for all the TMS-derivates of analytes and inter-
nal standards were obtained, following injections of methanolic standards (2 μl injected 
from a solution of 4.5 ng/µL) in full scan (Figure 15). The same injection was performed for 
































Figure 15: Chromatograms and MS-spectra for the TMS-derivates of the analytes and the TMS-

























































Figure 16: Chromatogram and MS-spectra for THC-COOHd9-2TMS. 
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Then, the most abundant product ions for each compound were chosen. The product 
scan for each ion was obtained at different collision energies. The 3 most abundant transi-
tions were chosen at the collision energy which gave the optimal fragmentation. 3 transi-
tions for each analytes were chosen in order to be able to have a quality control for the 
analysis.  One quantification transition was chosen per compound, considering abundance in 
spiked urine and specificity. For chromatograms of THC-TMS, THC-OH-2TMS, THC-COOH-
2TMS and the TMS-derivates of the d3-analogues, see figure 17. 
 
Table 8: Parent ion, transitions, collision energy and the retention time chosen for the TMS-derivates of ana-















































6.76 479.3-301.3 25 
306.3-271.3 30 
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According to the instruments settings (column), the retention times could shift form one 

















































Figure 17: GC-TSQ chromatogram of the TMS-derivates of the analytes and the TMS-derivates of the internal 






In this experiment, three different GC-MS methods (changes in column type, pressure, 
oven ramping) were first used. Interference have been observed in each of the methods 
tested (Figure 18) and thus GC-MS appeared not to be optimal for detection of cannabinoids 























Figure 18: Negative urine injected in GC-MS. The arrows are indicating interfering signals for THC-COOH-
2TMS. 
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The negative urines were compared to spiked urine (50 ng/mL of standards and internal 
standards) and examined for interfering signals (Figure 19). There were signals for THCd3-
TMS (transition 374.3-292.4) and THC-OH-2TMS (transition 305.3-158.1 and 459.4-368.4), 



































Figure 19: Negative urine from volunteer 2 injected in GC-TSQ. The chromatogram of THC-COOHd9-2TMS, 
internal standard used in this experiment, can be seen to the left in the chromatogram. The coelutions with a 
retention time close to the standards are shown. 
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6.3 Linearity and detection limits 
Due to instrumental problems, only urine samples obtained from one person were ana-
lyzed in the concentration range 0.1 500 ng/mL. Hence, the estimates and further discussion 
of linearity, LOD, LLOQ and ULOQ are based on these data only. 
 
The standard curves of THC, THC-OH and THC-COOH in the concentration range 0.1-9 
ng/mL (further referred to as the lower concentrations) and 0.1-500 ng/mL were obtained 
(Figure 20). Considering the small concentration range, more samples have been extracted 
and analyzed to have a better estimation of LOD and LLOQ and also to avoid an analytical 
bias with higher concentrations. Indeed, when the concentrations of 100 and 500 ng/mL 
were introduced in the plot (Figure 20) the equation of the regression curve (slope and in-
tercept) and the calculated concentrations changed (Table 10). 
All the linearity coefficients are satisfying (R2>0.995), except for THC at the lower concen-
tration area. This suggest that the method is stable for THC-OH and THC-COOH, but not for 
















































Figure 20: The standard curves for THC, THC-OH and THC-COOH in the concentration range 




y = 0.0155x + 0.0068
R² = 0.9644
y = 0.0344x + 0.0013
R² = 0.9961

























Standard curve - range 0.1-9 ng/mL
THC THC-OH THC-COOH
y = 0.0131x + 0.0368
R² = 0.9989
y = 0.028x + 0.0232
R² = 1
























Standard curve - range 0.1-500 ng/mL
THC THC-OH THC-COOH
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The equations obtained from the standardcurves were used to calculate the concentra-
tions (0.1, 0.5, 1, 3, 5, 7, 9, 100 and 500 ng/mL), and a 2 by 2 plot was done with the theoret-
ical concentration (Figure 21- 23). 
The correlation between the theoretical and calculated values is expressed by a function, 
and hence a curve, where y is the recalculated values and x is the theoretical values, and a, 
the slope, is describing the correlation between these values. A slope and a regression coef-






























Figure 21: The curve shows the relationship between the theoretical and the calculated val-






































Figure 22: The curve shows the relationship between the theoretical and the calculated val-






































Figure 23: The curve shows the relationship between the theoretical and the calculated val-
ues for THC-COOH (concentrationrange 0.1-9 ng/mL and 0.1-500 ng/mL). 
 
 
The point at 0.5 ng/mL deviates from the curve (Figure 20-23). This is probably due to an 
error when spiking the samples. Thus, the linearity and correlation may be improved if the 
experiment is done again. 
The difference between the theoretical and calculated values can be expressed in per-
centage, and illustrates the uncertainty of the method. These values should not increase 
above a certain limit, which in this experiment was set to 17 %. This value was obtained from 
the validation for the quantification of THC-COOH on the Swiss Laboratory for Doping Analy-
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sis[3]. For table over the theoretical and the calculated values, see table 9. For table over 
theoretical and the biased calculated values, see table 10. 
The correlation is better for the higher concentrations, because the method is more 
stable in this range. 
 
Table 9: The difference between the true and the calculated values 
 
 
Table 10: The difference between the theoretical and the calculated values (biased) 
 
Regarding THC, the values in table 9 connfirmes the results obtained from the curve in 
Figure 21. For the lower concentrations, the percentage difference (table 10) is not sufficient 
below 7 ng/ml, which indicates that the method is unstable in the lower concentration 
range. This is confirmed qualitatively (upper curve, Figure 21) and by R2, (Figure 20 and 21)  
For THC-OH and THC-COOH, the linearity coefficient (Figure 22 and 23) indicates a stable 
method in the lower concentration range. This can also be confirmed qualitatively (Figure 22 
and 23), and by the percentage differences in table 10. For THC-OH the percentage 
difference is sufficient at concentrations ≥1 ng/ml, and for THC-COOH, the percentage 
difference is sufficient at concentrations ≥ 3ng/ml. 
 
Theoretical values 
Calculated values Difference between values (%) 
THC THC-OH THC-COOH THC THC-OH THC-COOH 
0.1 ng/ml -0.3 0.0 0.0 424.2 88.3 92.7 
0.5 ng/ml 0.8 0.8 0.8 -61.3 -62.3 -54.3 
1 ng/ml 0.9 0.9 0.7 14.2 10.1 25.0 
3 ng/ml 2.5 2.7 2.9 16.7 10.0 2.1 
5 ng/ml 6.3 5.1 5.1 -25.6 -1.8 -2.4 
7 ng/ml 7.2 7.2 7.2 -2.7 -3.3 -3.4 
9 ng/ml 8.3 8.9 8.8 7.3 1.3 2.3 
100 ng/ml 114.3 99.7 100.0 -14.3 0.3 0.0 
500 ng/ml 498.2 500.9 499.9 0.4 -0.2 0.0 
Theoretical values 
Calculated values (biased) Difference between values (%) 
THC THC-OH THC-COOH THC THC-OH 
THC-
COOH 
0.1 ng/ml -2.7 -0.8 -0.8 2773.7 867.7 899.3 
0.5 ng/ml -1.3 0.2 0.1 367.2 57.0 73.2 
1 ng/ml -1.3 0.3 0.1 227.4 67.8 89.3 
3 ng/ml 0.7 2.5 2.8 77.8 15.5 7.4 
5 ng/ml 5.1 5.5 5.4 -2.8 -9.4 -8.9 
7 ng/ml 6.2 8.1 8.0 11.3 -15.7 -14.7 
9 ng/ml 7.6 10.1 9.9 15.8 -12.6 -10.4 
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Since THC and THC-OH are not implemented in screening and quantification of cannabis, 
no cut-off limit is set. The cut-off limit for THC-COOH is 15 ng/mL, all samples above this lev-
el are considered as adverse analytical findings.  
Cannabis has doping potential when used the day before a competition, thus it will be 
useful if the analytes are detectable for 24 hours in urine. 
The urinary concentration of THC and THC-OH of light cannabis smokers were detected in 
levels ≥ 0.1 ng/ml THC and ≥ 0.1 ng/ml THC-OH after 2-8 hours and 12-72 hours respectively 
[32]. In order to verify cannabis consumption the day before a competition these com-
pounds should be detectable and quantifiable in these concentrations. As the limit from 
WADA regarding THC-COOH is 15 ng/mL, there is no need to detect this compound in lower 
concentration in this project.  
The same study[32] analyzed urine samples obtained from the Swiss Laboratory for Dop-
ing Analysis, and quantified THC, THC-OH and THC-COOH in concentrations of 68 ng/mL, 
213.6 ng/mL and 982.9 ng/mL respectively. Higher concentrations of these compounds in 
the samples may occur, thus the ULOQ in this experiment are suggested to be 100 ng/mL, 
250 ng/mL and 1000 ng/mL for THC, THC-OH and THC-COOH respectively. 
LLOQ are defined as signal to noise ratio ≥10, and LOD are defined as a signal to noise ra-
tio ≥ 3. The mean values of the S/N in 6 different samples should be calculated to obtain 
these values. 
Due to coeluting peaks in the chromatogram the noise was not obtained. Therefore, LOD 
and LLOQ were estimated qualitatively for THC, THC-OH and THC-COOH (table 11). The esti-
mated values for THC and THC-OH are higher than the preferred concentrations, but the 
signal to noise ratio should be obtained to get a more accurate measurement before any 
conclusions are drawn. 
Regarding ULOQ, the curve will change from linear to parabolic when the signal is satu-
rated. The curve was still linear at 500 ng/mL for all the analytes; hence the ULOQ in this 
experiment was estimated to that value.  
The estimated ULOQ is satisfactory regarding the quantification for THC and THC-OH, but 




Table 11: LOD, LLOQ and ULOQ for THC, THC-OH and THC-COOH 
 
LLOQ and LOD in this experiment are too high regarding THC and THC-OH and the regres-
sion coefficient indicates an unstable sample preparation for THC in the lower concentration 
area. Also the uncertainty is not satiyfying regarding the desired concentrations for THC and 
THC-OH.  
The regression coefficient for THC-OH and THC-COOH are sufficient, and so are the LLOQ 
and LOD for THC-COOH. However, the detectionlimits were qualitatively determined and 
should be measured more precisely before any conclusions are drawn. Also, further mea-
surement should be done regarding uncertainty for THC and THC-OH and regression coeffi-
cient and uncertainty for THC in the lower concentration range, to see if these values were 
due to errors when preparing the samples. Therefore, the method should be validated fur-
ther. 
6.4 Quantification of “true” samples 
9 different urine samples from THC-consumers with a THC-COOH-concentration of 0.00, 
15.22, 15.61, 15.72, 49.70, 100.10, 255.83, 502.56 and 947.84 ng/mL (previously quantified 
with GC-MS) was added internal standards, β-glucuronidase and phosphate buffer.  
For the calibration curve, negative urine were spiked with different quantities of standard 
solution to contain the following concentrations of the standards; 0, 0.1, 0.5, 1, 5, 10, 50, 
100, 500 and 1000 ng/mL. The standards were evaporated before adding urine, enzyme, 
phosphate buffer and internal standard. 
All the samples were added β-glucuronidase, phosphate buffer and internal standards, 
extracted, evaporated and derivatized with (50 μl MSTFA, 20 minutes, 90°C). 
 LOD LLOQ ULOQ 
THC 5 ng/ml 5 ng/ml 500 ng/ml 
THC-OH 5 ng/ml 5 ng/ml 500 ng/ml 
THC-COOH 3 ng/ml 3 ng/ml 500 ng/ml 
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Unfortunately, the retention time was changing during this experiment, see Figure 24, 
hence no results were obtained from this experiment. 
Figure 24: Negative urine from volunteer 2 injected in GC-TSQ, scan mode. The retentiontime for THC-
COOHd9-2TMS is changing with over a half minute.
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7 Trouble shootings 
Several problems appeared during the accomplishment of this project. A lot of efforts have 
been made to resolve them at the time they emerged which is the main reason of the non 
achievement of some of the aims. 
It is important to mention here few of these problems and to present the way that they 
have been treated. 
 Technical problems with the GC-MS/MS instrument                                                      
In most cases, analyses based on GC-MS/MS in the MRM mode are superior to 
the use of GC-MS in SIM-mode. However, a lot of technical problems with the in-
strument were experienced. Considerable time and effort was allocated to solve 
these problems, and this had great impact on the progress of the project. 
 Change in retention time 
During the large injection sequences that have been done on the GC-TSQ, the re-
tention times of the investigated compounds changed in a significant manner. One 
of the advantages of gas chromatography is its stable RT. Retention time is a key 
factor to evaluate different steps (specificity, LOD, LOQ,…) in the validation 
process of an analytical method. Therefore, these shifts in the RT had to be fixed 
before going further in the validation process. After many investigations, a leak in 
the gas system was discovered and then the RT was much more stable for a cer-
tain period of time which allowed the analyses of the specificity samples. 
Then the same trouble reappeared and it was thought that the problem was due 
to the derivatization agent since this was not adapted to the GC column installed 
(HP-1 MS). As acetonitrile was put in the final derivatization mixture, the polarity 
of this solvent could destroy rapidly the stationary phase inside the column. 
Another derviatization agent (MSTFA) has been tried as this has been demonstrat-
ed to be compatible with the GC column. Once again this solution did not resolve 
the troubles related to the RT.   
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 Missing signals. 
In some parts of the project, no signals (peaks) were obtained for the com-
pounds, even not when methanolic standards were injected in full scan. This loss 
was probably related to a leak in the system and contamination of the ion source.  
 Missing scans 
At some point of the project, scans coming from the acquisition system were miss-
ing. This was submitted again to the technician who had to come over in the la-
boratory to check all the electronics devices and fixed the problem. 
 Sample preparation 
During the phase of sample preparation testing (LLE, reversed phase SPE and 
mixed mode SPE), a loss of sensitivity and even total loss of signal were observed 
for a long time. Many investigations were done on the machine for few days until 
the sample preparation itself was reconsidered. Indeed, buffers and solutions that 
were used in the sample preparations were more than a month old and therefore 
outdated. Fresh solutions were done and signal and sensitivity came back. 
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8 Conclusion and perspectives 
This report reflects eight months of work and efforts. During this project, introductions 
to methods used in doping analyses have been given. The work has been instructive but also 
frustrating. 
A GC-TSQ method and a sample preparation for detection of THC, THC-OH and THC-
COOH in urine have been developed, validated for specificity and evaluated for linearity, 
LLOQ, ULOQ and LOD. Due to several problems during the project, the method was not fully 
validated. Even though problems prevented achievement of the initial aims, resolution of 
the trouble shootings linked to the instrument have been instructive and allowed 
acquirement of practical and theoretical aspects of working with a GC-TSQ. 
Different sample preparations and conditions for hydrolysis were tested. The final 
extraction procedure includes an enzymatic hydrolysis with 8250 U/mL β-glucuronidase at 
37°C for 16 hours followed by a mixed mode SPE sample preparation. Working with different 
types of instruments has improved the previous knowledge of the practical and theoretical 
aspects of GC-MS. The MRM transitions chosen during the method development revealed to 
be specific and adapted for the quantification of THC and its metabolites in urine matrix.  
The results and discussion regarding the linearity and detection limits suggest that the 
method should be further validated.  
Anyhow, the method is useful basis for further work. 
Further, a MRM-method for the THC-analogues should be developed; using the same 
procedure as used for THC, THC-OH and THC-COOH, and a sample preparation should be 
developed, validated and implemented in the screening procedure in the Swiss Laboratory 
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9.1 Herbal blends 
In 2004 herbal mixtures called ‘Spice’ was introduced on the marked, mainly via internet. 
They come in different versions, i.e. Spice Gold, Spice Silver, Spice Diamond, Spice Arctic 
Synergy, Tropical Spice and Spice Egypt. Other herbal blends, which say they have the same 
content as Spice, examples of these are Yuacatan Fire, Smoke, Sence and ChillX, are also 
available [49].  
The herbal blends are declared incense and not for human consumption. Despite of this, 
they are smoked. Users have described cannabis-like effect after consuming these blends, 
but cannabis cannot be detected and the narcotic effects was suggested to be caused by 
added synthetic compounds or plant extracts [50]. Late in 2008 JWH-018 ((1-pentil-3-(1-
naftoil)indol) [49]) was detected in one of the Spice products. Shortly after, CP47,497 (5(1-
dimetilheptil – 2 ((1R,3S) – 3 hydroxycyclohexyl) [49] was also detected in a Spice product 
[49, 50]. Both these compounds are defined as synthetic cannabinoids [50]. After the 
detection in the mixtures, the Spice products was prohibited several countries of the EU 
[49]. In march 2009, another synthetic cannabinoid, HU-210 (6aR,10aR)- 9-(Hydroxymethyl)- 
6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol), was 
detected in some herbal blends (Spice Gold, Spice Silver, Spice Diamond, Geni and Yuacatan 
Fire) by the Drug Enforcement Administration in USA [49, 51]. At the same time JWH-018 
was replaced by the analogue JHW-073 ((Naphthalene-1-yl-(1-butylindol-3-yl)methanone 
[52]) [50].  
The cannabinoid analogues act agonistically on the receptors CB1 and CB2 [53], and are 
classified into several groups. CP49,497 belongs to the non classic cannabinoids, which are 
bicyclic or tricyclic compounds [49]. The CP47,497 has 3-28 times greater potency compared 
with THC (depending on the applied model) [54] and the affinity for CB1 is 20 times greater 








Molecular weight: 318.5g/mol  
Monoisotopic mass: 318.3 u  
pKa: 10.80  
Average logP: 6.25 (±0.81)  
 
Figure 25: Structure, molecular weights (MW) and pKa-values for CP47, 497. The pKa-values and the logP 
are predicted values [46, 47] 
 
 
The group aminoalkaloides includes JWH-018, JWH-073, JWH-200 and JWH-250. The 
compounds in this group have a chemistry structure different from the other groups.  
When compared to THC, JWH-018 has a 4 times greater potency for the CB1 receptor and 10 
times greater potency for the CB2 receptor. In studies on rats, JWH-018 diminished 
locomotive activity, produced analgesia, hypothermia and catalepsy in a similar way that 
THC does. JWH-073 mainly affects CB1, but has a similar affinity of CB2 as that of THC. In the 
same way as JWH-018, the analogue JWH-073 will affect locomotive activity and produce 
analgesia and hypothermia similar to THC. There are no studies on catalepsy effects 
regarding this compound [49].   
JWH 200 (1-[2-(4-Morpholino)ethyl]-3-(1-naphthoyl)indole) binds to CB1-receptor with a Ki 
42 +- 5 nM [55]. The Ki-value is the inhibition constant for a drug; the concentration for a 
drug which would occupy 50 % of the receptors if no competing ligand was present. A study 
on mice have shown that JWH-200 have the same or superior effects in locomotor activity, 
tail-flick latency, hypothermia, and ring-immobility tests as THC[56]. 
JWH-250 (2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone) [52] was detected in May 
2009 in spice products [52]. The compound has a high affinity for CB1 and CB2 receptors 
with a Ki = 11 nM and Ki = 33 nM, respectively. These values are a bit smaller than those for 
the THC (Ki = 40.7 nM and 36.4 nM respectively) [57, 58]. For structural formulas of JWH-










Molecular weight: 371.5 g/mol Molecular weight: 341.5 g/mol 
Monoisotopic mass: 335.2 u Monoisotopic mass: 341.8 u 








   
JWH-073 JWH-200 
Molecular weight: 327.5 g/mol  Molecular weight: 384.5 g/mol 
Monoisotopic mass: 327.2 u Monoisotopic mass: 384.2 u 
LogP: 5.91 (±0.50) Average logP: 4.21    
 pKa: 6.60 
    
 
Figure 26: Structure, molecular weights (MW) and pKa-values for JWH-250, JWH-018, JWH-073 and JWH-200. 
The pKa-values and the logP are predicted values [46, 47] 
 
The last two groups of cannabinoids are classical cannabinoids (dibenzopyranoids) and 
endocannabinoids (eicosanoids). The first group includes THC and consists of a tricyclic 
structure. The compounds in the latter one are produced endogenously, and the majority of 
this group are derivates of arachidonic acid [49]. 
There are several problems with the human intake of these different blends. First of all, 
the only existing studies on the compounds (JWH-018, JWH-073, JWH-200, JWH-250 and 
CP47,497) are in test-tubes or with experimental animals. Thus, little is known about the 
safety and effects in humans [49]. Second, batch-to-batch-variation in the kind and differ-
ences in the amount of drug used can cause accidental overdosing [54]. And third, because 
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of the ease of synthesis of JWH-018  analogues, these could easily replace each other in legal 
replacement products [50]. It is also reason to be concerned about induction of psychic 
problems due to use of spice-products, since these compounds have cannabinoid-like ef-
fects. In a case report reactivation of psychotic symptoms after abuse of “Spice” was re-
ported [59] 
Because of the cannabinoid effects of Spice-products, there is a risk that these kinds of 
compounds could be used as performance-enhancing agents in sports, and thereby activate 
psychic problems among athletes. Thus, it is important to have a method for detection of 
these compounds in urine.  
9.1.1 Current chromatographic methods for detection of cannabinoid ana-
logues 
Since these analogues are newly introduced into the marked, the literature on this field is 
limited. By start of this project, it was as far as I know, no published work regarding GC-
MS/MS analysis of these compounds. However, in march 2010, a liquid-chromatography (LC) 
tandem MS method for quantification of JWH-018 in human serum was accepted in a journal 
[60]. In another accepted article, JWH-018, CP-47,497 and JWH-073 in herbal products were 
identified and analysed using GC-MS and LC-MS. The MS-spectra and a sample preparation 
of these herbal products were presented [61].  
Two published articles have also managed to detect JWH-018 in herbal samples by GC-MS 
[50, 54], the same applies for JWH-073 [50]. CP49,497, JWH-018 and JWH-073 have also 
been detected by LC-MS [61] 
 
